Cesar Margarit Ferri1, Silvia Natoli2, Paz Sanz-Ayan3, Alberto Magni4, Carlos Guerrero5, Argelia Lara-Solares6, Hiltrud Liedgens7, Guido Thömmes8, Ravi Karra9. 1. Hospital General Universitario de Alicante, Alicante, 03010, Spain. 2. University of Rome Tor Vergata, Department of Clinical Science & Translational Medicine & Unit of Pain Therapy, Polyclinic of Tor Vergata, Rome, 00133, Italy. 3. Hospital Universitario 12 de Octubre; Department of Rehabilitation, Hospital Universitario 12 de Octubre, Madrid, 28041, Spain. 4. Italian College of General Practitioners & Primary Care, Florence, 50141, Italy. 5. Hospital Universitario Fundación Santa Fe, Bogotá 110121, Universidad de los Andes, Colombia. 6. Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, 14080, Mexico. 7. Global Market Access, Grünenthal GmbH, Aachen, 52099, Germany. 8. R&D - Development - Data Sciences, Grünenthal GmbH, Aachen, 52099, Germany. 9. Global Medical Affairs, Grünenthal GmbH, Aachen, 52099, Germany.
Abstract
Aims: To investigate quality of life (QOL) and functionality changes in chronic pain during tapentadol prolonged release (PR) treatment. Patients & methods: Post hoc analysis of data from three Phase III trials in patients with osteoarthritis knee pain or low back pain. QOL and functionality changes were assessed by SF-36 scores. Results: All SF-36 subdomain scores improved progressively to week 3 of tapentadol titration and were sustained during 12-week maintenance treatment. Improvements in SF-36 scores were similar between tapentadol dose groups (e.g., 200 to <300 mg vs ≥500 mg), with no greater effect from higher doses. QOL and functionality improvements were consistently greater with tapentadol PR than oxycodone controlled release. Conclusion: Tapentadol PR provides consistent, clinically relevant improvements in QOL and functionality in chronic pain.
Aims: To investigate quality of life (QOL) and functionality changes in chronic pain during tapentadol prolonged release (PR) treatment. Patients & methods: Post hoc analysis of data from three Phase III trials in patients with osteoarthritis knee pain or low back pain. QOL and functionality changes were assessed by SF-36 scores. Results: All SF-36 subdomain scores improved progressively to week 3 of tapentadol titration and were sustained during 12-week maintenance treatment. Improvements in SF-36 scores were similar between tapentadol dose groups (e.g., 200 to <300 mg vs ≥500 mg), with no greater effect from higher doses. QOL and functionality improvements were consistently greater with tapentadol PR than oxycodone controlled release. Conclusion:Tapentadol PR provides consistent, clinically relevant improvements in QOL and functionality in chronic pain.
Entities:
Keywords:
SF-36; functional outcomes; functionality; health-related quality of life; mental health outcomes; oxycodone; physical health outcomes; tapentadol PR
Authors: Ji Yoon Jung; Hong Jae Chon; Young Jin Choi; Sang Eun Yeon; Seok Young Choi; Kyung Hee Lee Journal: Support Care Cancer Date: 2022-04-14 Impact factor: 3.359